Unknown

Dataset Information

0

Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma.


ABSTRACT: Invasive lobular breast carcinoma (ILC) is the second most common breast carcinoma (BC) subtype and is mainly driven by loss of E-cadherin expression. Correct classification of BC as ILC is important for patient treatment. This study assessed the degree of agreement among pathologists for the diagnosis of ILC. Two sets of hormone receptor (HR)-positive/HER2-negative BCs were independently reviewed by participating pathologists. In set A (61 cases), participants were provided with hematoxylin/eosin (HE)-stained sections. In set B (62 cases), participants were provided with HE-stained sections and E-cadherin immunohistochemistry (IHC). Tumor characteristics were balanced. Participants classified specimens as non-lobular BC versus mixed BC versus ILC. Pairwise inter-observer agreement and agreement with a pre-defined reference diagnosis were determined with Cohen's kappa statistics. Subtype calls were correlated with molecular features, including CDH1/E-cadherin mutation status. Thirty-five pathologists completed both sets, providing 4,305 subtype calls. Pairwise inter-observer agreement was moderate in set A (median κ = 0.58, interquartile range [IQR]: 0.48-0.66) and substantial in set B (median κ = 0.75, IQR: 0.56-0.86, p < 0.001). Agreement with the reference diagnosis was substantial in set A (median κ = 0.67, IQR: 0.57-0.75) and almost perfect in set B (median κ = 0.86, IQR: 0.73-0.93, p < 0.001). The median frequency of CDH1/E-cadherin mutations in specimens classified as ILC was 65% in set A (IQR: 56-72%) and 73% in set B (IQR: 65-75%, p < 0.001). Cases with variable subtype calls included E-cadherin-positive ILCs harboring CDH1 missense mutations, and E-cadherin-negative ILCs with tubular elements and focal P-cadherin expression. ILCs with trabecular growth pattern were often misclassified as non-lobular BC in set A but not in set B. In conclusion, subtyping of BC as ILC achieves almost perfect agreement with a pre-defined reference standard, if assessment is supported by E-cadherin IHC. CDH1 missense mutations associated with preserved E-cadherin protein expression, E- to P-cadherin switching in ILC with tubular elements, and trabecular ILC were identified as potential sources of discordant classification.

SUBMITTER: Christgen M 

PROVIDER: S-EPMC8822373 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma.

Christgen Matthias M   Kandt Leonie Donata LD   Antonopoulos Wiebke W   Bartels Stephan S   Van Bockstal Mieke R MR   Bredt Martin M   Brito Maria Jose MJ   Christgen Henriette H   Colpaert Cecile C   Cserni Bálint B   Cserni Gábor G   Daemmrich Maximilian E ME   Danebrock Raihanatou R   Dedeurwaerdere Franceska F   van Deurzen Carolien Hm CH   Erber Ramona R   Fathke Christine C   Feist Henning H   Fiche Maryse M   Gonzalez Claudia Aura CA   Ter Hoeve Natalie D ND   Kooreman Loes L   Krech Till T   Kristiansen Glen G   Kulka Janina J   Laenger Florian F   Lafos Marcel M   Lehmann Ulrich U   Martin-Martinez Maria Dolores MD   Mueller Sophie S   Pelz Enrico E   Raap Mieke M   Ravarino Alberto A   Reineke-Plaass Tanja T   Schaumann Nora N   Schelfhout Anne-Marie AM   De Schepper Maxim M   Schlue Jerome J   Van de Vijver Koen K   Waelput Wim W   Wellmann Axel A   Graeser Monika M   Gluz Oleg O   Kuemmel Sherko S   Nitz Ulrike U   Harbeck Nadia N   Desmedt Christine C   Floris Giuseppe G   Derksen Patrick Wb PW   van Diest Paul J PJ   Vincent-Salomon Anne A   Kreipe Hans H  

The journal of pathology. Clinical research 20211210 2


Invasive lobular breast carcinoma (ILC) is the second most common breast carcinoma (BC) subtype and is mainly driven by loss of E-cadherin expression. Correct classification of BC as ILC is important for patient treatment. This study assessed the degree of agreement among pathologists for the diagnosis of ILC. Two sets of hormone receptor (HR)-positive/HER2-negative BCs were independently reviewed by participating pathologists. In set A (61 cases), participants were provided with hematoxylin/eos  ...[more]

Similar Datasets

| S-ECPF-NCMF-3 | biostudies-other
2010-08-20 | E-NCMF-3 | biostudies-arrayexpress
| S-EPMC3849530 | biostudies-literature
| S-EPMC11466385 | biostudies-literature
| S-EPMC3163683 | biostudies-literature
| S-EPMC3346022 | biostudies-literature
| S-EPMC9432355 | biostudies-literature
| S-EPMC7805167 | biostudies-literature
| S-EPMC10340059 | biostudies-literature
| S-EPMC9137964 | biostudies-literature